موافقات الدواء

Ozenoxacin is indicated for the topical treatment of impetigo in patients aged 2 months and older.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ozanex and other antibacterial drugs, Ozanex should be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.